A study of over 85,000 women found that insurance coverage and healthcare access significantly affect folic acid use, increasing preventable birth defect risks. The findings support fortification efforts, while a University of Houston initiative aims to address pharmacy access barriers.
San Francisco's RESET Center opens Monday in SoMa to take in people found publicly using drugs or intoxicated. Officials have offered conflicting explanations about arrest status, detention, release rules and medication access.
Eli Lilly has launched two Phase 2 trials for brenipatide (LY3537031): RENEW-Op-1 for opioid use disorder and RENEW-Scz-1 for schizophrenia. Both are randomized, double-blind, placebo-controlled studies that are not yet recruiting as of February 2026.
Eli Lilly launched the monthly Zepbound KwikPen for obesity treatment and initiated a Phase 2 trial for opioid use disorder, while Gilead Sciences agreed to acquire Arcellx for $7.8 billion to expand its cell therapy portfolio.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07420283 |
A Study of Brenipatide in Participants With Opioid Use Disorder |
RECRUITING | PHASE2 |
| NCT07176351 |
Acceptability and Feasibility of Extended-Release Subcutaneous Buprenorphine on a Mobile Pharmacy Clinic |
NOT_YET_RECRUITING | PHASE4 |
| NCT06379984 |
Rapid Outpatient Low-dose Initiation of Buprenorphine for OUD With Fentanyl Use |
RECRUITING | PHASE2 |
| NCT06133114 |
Psychopharmacological Treatment of Emotional Distress |
WITHDRAWN | PHASE4 |
| NCT04276259 |
Rapid Antidepressant Improvement Secondary to Excitatory Brain Responses |
COMPLETED | PHASE4 |
| NCT03511118 |
Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants |
RECRUITING | |
| NCT02526212 |
Buprenorphine Group Medical Visits in Primary Care |
COMPLETED | PHASE3 |
